Sign in
SuspendedNo phase

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

Key facts

Who runs it
Rutgers, The State University of New Jersey
Where
Livingston and New Brunswick, United StatesSee the 2 sites
Trial code
Status
Suspended
People taking part
30 people, planned
Started
29 Apr 2021
Expected to end
1 Sept 2027
Type of study
Interventional
Treatments tested
  • Biospecimen Collection - blood and tissue sample collection
  • Electronic Health Record Review
Record updated
4 May 2026
Why it stopped
Pending Protocol amendment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients with histologically confirmed carcinoma of presumed gastrointestinal origin (gastric, esophageal, colorectal, appendiceal, hepatobiliary or peritoneal carcinomatosis of apparent GI primary) with documented diffuse peritoneal carcinomatosis, either by conventional imaging studies, positive ascitic fluid analysis, or surgical staging
  • Measurable or evaluable disease by cross-sectional imaging studies
  • Patients must be candidates for possible surgical cytoreduction (with or without HIPEC) as determined by a study surgical oncologist
  • Age >= 18 years
  • Estimated life expectancy of at least 12 months
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Patients must sign informed consent
  • Be willing to present for medical exams, blood draws and imaging as scheduled in protocol
  • Be able to donate two 10 mL tubes of blood every 3 months
  • Women of childbearing potential will undergo routine screening evaluation for pregnancy prior to enrollment and be managed per standard of care

Who cannot take part

  • Patients who cannot undergo a therapeutic surgical cytoreduction
  • Bone marrow transplant or other organ transplant recipient
  • Any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening
  • Patients with cardiovascular or pulmonary risk factors contributing to high risk for surgical complications, at the discretion of the surgeon
  • Serious concomitant systemic disorder that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
  • Second uncontrolled primary malignancy
  • Patients without a confirmed pathologic diagnosis of carcinoma
  • Patients who are pregnant

Where in United States

  • RWJBarnabas Health - Cooperman Barnabas, LivingstonLivingston, United States
  • Rutgers Cancer Institute of New JerseyNew Brunswick, United States

About the trial

What the trial wants to find out

This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and function. Everyone is born with the same DNA in all our cells throughout our body. Sometimes, some of the cells in the body develop abnormalities in the DNA that cause those cells to grow abnormally and uncontrollably. Cancer occurs when there is abnormal and uncontrolled growth of cells. The DNA in cancer cells is therefore different from the DNA someone is born with. The Signatera ctDNA assay is a laboratory test that takes tumor (cancer) tissue and evaluates it for unique tumor DNA. This evaluation is used to create a report (otherwise known as an assay) personalized to each person's cancer. The personalized assay creates a personalized blood test to detect the level of abnormal DNA from the cancer that may be circulating in the body. Once this personalized blood assay is designed, it may be used to monitor a person's blood for the presence of ctDNA, which will indicate the presence or absence of cancer over time, even after treatment.

The group in the trial

  • Diagnostic (biospecimen collection)Treatment being tested

    Patients will receive standard treatment with surgery, HIPEC, and chemotherapy as appropriate to the patient situation, extent of disease and multi-disciplinary evaluation. Patients undergo blood sample collection for ctDNA analysis at baseline, pre-surgery, post-surgery and every 3 months up to 2 years. Patients undergo tissue collection before or during surgery and their medical records are reviewed.

    Treatment: Biospecimen Collection - blood and tissue sample collection and Electronic Health Record Review

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 May 2026